Jon D. Morrow

651 total citations
17 papers, 524 citations indexed

About

Jon D. Morrow is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Jon D. Morrow has authored 17 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Urology, 12 papers in Rheumatology and 9 papers in Epidemiology. Recurrent topics in Jon D. Morrow's work include Urinary Bladder and Prostate Research (14 papers), Pelvic floor disorders treatments (12 papers) and Urinary Tract Infections Management (9 papers). Jon D. Morrow is often cited by papers focused on Urinary Bladder and Prostate Research (14 papers), Pelvic floor disorders treatments (12 papers) and Urinary Tract Infections Management (9 papers). Jon D. Morrow collaborates with scholars based in United States, Netherlands and Belgium. Jon D. Morrow's co-authors include Zhonghong Guan, Jason Gong, Franklin Sun, Rebecca G. Rogers, Tamara Bavendam, Steven Swift, Marina Brodsky, Sender Herschorn, Martin Carlsson and David Staskin and has published in prestigious journals such as The Journal of Urology, Urology and British Journal of Urology.

In The Last Decade

Jon D. Morrow

15 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon D. Morrow United States 11 483 441 254 110 67 17 524
Hans-Theo Forst Germany 2 342 0.7× 264 0.6× 171 0.7× 76 0.7× 53 0.8× 4 355
Gerd Mürtz Germany 13 535 1.1× 444 1.0× 275 1.1× 40 0.4× 36 0.5× 22 578
Asha Paireddy United States 8 425 0.9× 339 0.8× 269 1.1× 66 0.6× 13 0.2× 11 460
Regula Doggweiler United States 5 232 0.5× 241 0.5× 71 0.3× 59 0.5× 12 0.2× 11 310
David Holmes United Kingdom 8 200 0.4× 273 0.6× 87 0.3× 148 1.3× 9 0.1× 19 380
Budiwan Sumarsono South Korea 10 352 0.7× 299 0.7× 189 0.7× 39 0.4× 6 0.1× 22 402
Caty Ebel‐Bitoun France 6 186 0.4× 188 0.4× 119 0.5× 24 0.2× 9 0.1× 11 276
Sheila O. Brown United States 4 243 0.5× 169 0.4× 77 0.3× 24 0.2× 8 0.1× 6 291
Rainer Lange Germany 8 195 0.4× 302 0.7× 126 0.5× 178 1.6× 2 0.0× 14 339
Jori S. Pesonen Finland 6 91 0.2× 100 0.2× 38 0.1× 67 0.6× 1 0.0× 11 183

Countries citing papers authored by Jon D. Morrow

Since Specialization
Citations

This map shows the geographic impact of Jon D. Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon D. Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon D. Morrow more than expected).

Fields of papers citing papers by Jon D. Morrow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon D. Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon D. Morrow. The network helps show where Jon D. Morrow may publish in the future.

Co-authorship network of co-authors of Jon D. Morrow

This figure shows the co-authorship network connecting the top 25 collaborators of Jon D. Morrow. A scholar is included among the top collaborators of Jon D. Morrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon D. Morrow. Jon D. Morrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Foraker, Randi E., Jon D. Morrow, Julie A. Johnson, et al.. (2025). Understanding synthetic data: artificial datasets for real-world evidence. BMJ evidence-based medicine. bmjebm–2024.
3.
Mamik, Mamta M., Rebecca G. Rogers, Clifford Qualls, & Jon D. Morrow. (2014). The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire. International Urogynecology Journal. 25(10). 1321–1326. 27 indexed citations
4.
DuBeau, Catherine E., Jon D. Morrow, Stephen R. Kraus, Dana Creanga, & Tamara Bavendam. (2012). Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo‐controlled trials. Neurourology and Urodynamics. 31(8). 1258–1265. 22 indexed citations
5.
Staskin, David, Martin C. Michel, Franklin Sun, Zhonghong Guan, & Jon D. Morrow. (2012). The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms. The Journal of Urology. 187(5). 1721–1726. 5 indexed citations
6.
Staskin, David, Vik Khullar, Martin C. Michel, et al.. (2011). Effects of voluntary dose escalation in a placebo‐controlled, flexible‐dose trial of fesoterodine in subjects with overactive bladder. Neurourology and Urodynamics. 30(8). 1480–1485. 28 indexed citations
7.
Wyndaele, Jean‐Jacques, Evan R. Goldfischer, Jon D. Morrow, et al.. (2010). Patient‐optimized doses of fesoterodine improve bladder symptoms in an open‐label, flexible‐dose study. British Journal of Urology. 107(4). 603–611. 19 indexed citations
8.
Goldman, Howard B., Jon D. Morrow, Jason Gong, Li‐Jung Tseng, & Tim Schneider. (2010). Early onset of fesoterodine efficacy in subjects with overactive bladder. British Journal of Urology. 107(4). 598–602. 9 indexed citations
9.
Staskin, David, Martin C. Michel, Victor W. Νitti, et al.. (2010). Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. Current Medical Research and Opinion. 26(4). 813–818. 5 indexed citations
10.
Sand, Peter K., Jon D. Morrow, Tamara Bavendam, Dana Creanga, & Victor W. Νitti. (2009). Efficacy and tolerability of fesoterodine in women with overactive bladder. International Urogynecology Journal. 20(7). 827–835. 32 indexed citations
11.
Wyndaele, Jean‐Jacques, Evan R. Goldfischer, Jon D. Morrow, et al.. (2009). Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. International Journal of Clinical Practice. 63(4). 560–567. 67 indexed citations
12.
Rogers, Rebecca G., et al.. (2009). Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. International Urogynecology Journal. 20(4). 381–385. 21 indexed citations
13.
Dmochowski, Roger R., Kenneth M. Peters, Jon D. Morrow, et al.. (2009). Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. Urology. 75(1). 62–68. 78 indexed citations
14.
Herschorn, Sender, Steven Swift, Zhonghong Guan, et al.. (2009). Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial. British Journal of Urology. 105(1). 58–66. 132 indexed citations
15.
Brubaker, Linda, et al.. (2009). 64 CLINICAL VALIDITY OF A QUESTION TO MEASURE OVERALL SATISFACTION WITH TREATMENT FOR OVERACTIVE BLADDER SYMPTOMS. European Urology Supplements. 8(4). 136–136. 2 indexed citations
16.
Rogers, Rebecca G., Gloria Bachmann, Harriette M. Scarpero, et al.. (2009). Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion. 25(9). 2159–2165. 13 indexed citations
17.
Rogers, Rebecca G., Gloria Bachmann, Zhanna Jumadilova, et al.. (2008). Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. International Urogynecology Journal. 19(11). 1551–1557. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans-Theo Forst Breakdown of academic impact, for papers by Gerd Mürtz Breakdown of academic impact, for papers by Asha Paireddy Breakdown of academic impact, for papers by Regula Doggweiler Breakdown of academic impact, for papers by David Holmes Breakdown of academic impact, for papers by Budiwan Sumarsono Breakdown of academic impact, for papers by Caty Ebel‐Bitoun Breakdown of academic impact, for papers by Sheila O. Brown Breakdown of academic impact, for papers by Rainer Lange Breakdown of academic impact, for papers by Jori S. Pesonen
Rankless by CCL
2026